- COVID-19
- Biosimilars
- Cataract Therapeutics
- DME
- Gene Therapy
- Workplace
- Ptosis
- Optic Relief
- Imaging
- Geographic Atrophy
- AMD
- Presbyopia
- Ocular Surface Disease
- Practice Management
- Pediatrics
- Surgery
- Therapeutics
- Optometry
- Retina
- Cataract
- Pharmacy
- IOL
- Dry Eye
- Understanding Antibiotic Resistance
- Refractive
- Cornea
- Glaucoma
- OCT
- Ocular Allergy
- Clinical Diagnosis
- Technology
Warburg Pincus completes Lifecore offer
According to affiliates of private equity firm Warburg Pincus, a tender offer for all outstanding shares of Lifecore Biomedical Inc., a medical materials and device maker, is complete.
New York-According to affiliates of private equity firm Warburg Pincus, a tender offer for all outstanding shares of Lifecore Biomedical Inc., a medical materials and device maker, is complete.
The offer, which was worth $17 per share or about $229.5 million, concluded with about 94.2% of outstanding Lifecore shares tendered.
Investments in health care-related companies around the world add up to $6.2 billion for Warburg Pincus, according to the private equity firm, including $2.7 billion in medical device makers such as American Medical Systems, Bausch & Lomb, ev3, Kyphon, Tornier, and Wright Medical Group.
